If I'm reading that first graph correctly, which is for the whole tested population, the averaged pain reduction for iPPS is only at best about 6% less than the placebo. So what I'm interpreting is that for some severe pain sufferers a more substantial reduction is found ( previous announcement) , but averaged out over the whole population tested it does not look to be too impressive. Or am I dead wrong?
Ann: Paradigms Supplementary Phase 2B Data, page-4
Add PAR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
25.0¢ |
Change
0.015(6.38%) |
Mkt cap ! $87.44M | |||
| Open | High | Low | Value | Volume |
| 24.0¢ | 25.0¢ | 23.0¢ | $95.91K | 396.4K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 117676 | 24.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 25.0¢ | 36524 | 4 |
View Market Depth
| Last trade - 16.10pm 10/09/2024 (20 minute delay) ? |
| PAR (ASX) Chart |